ANZCTR search results

Our hypothesis is that with the combination of Photodynamic Therapy (PDT) and Ranibizumab patient would need fewer intravitreal injections. This would be of benefit to the patients in terms of reduced exposure to Ranibizumab as well as importantly a reduced risk of adverse events from the intravitreal injection procedure. In addition, there would be a benefit to the community with a in terms of reduced cost.

Single event Multilevel surgery, usually called SEMLS is a program that involves more than one operation on bones and or muscles carried out at the same time. The surgery is to correct problems that stop you being able to stand up straight and walk properly. The benefit of having the operations all at one time is that you only need to come into hospital once and be put to sleep once. No one has ever proved that the surgery is successful or measured exactly what differences the surgery makes. this is the aim of this study. To do this we are dividing the children who are going to have surgery into two groups. The timing of the surgery is not that important so one group will have surgery now and the other in a year's time. We will monitor both groups over this year allowing us to compare progress in both groups.

The primary purpose of this study is to see how much and how fast vitamin D is absorbed into the skin when combined with the penetration enhancer tocopheryl phosphate mix (TPM) and to then compare it to vitamin D alone.

This trial is investigating opioid dose-sparing, analgesic efficacy and quality of post-operative pain relief provided by multimodal analgesic regimens based on patient controlled epidural pethidine together with placebo, cyclo-oxygenase 2 enzyme (COX-2) inhibitors, paracetamol or COX-2 inhibitors and paracetamol in combination, in women receiving regional anaestheisa for elective caesarean section.

The Quit Smoking in General Practice study will test the uptake and effectiveness of enhanced in-practice support for smoking cessation compared to 2 other interventions, referral to Quitline and normal GP intervention (control group). The in-practice intervention (Quit in General Practice) involves flexible support for quitting provided primarily by the PN in partnership with the patient’s GP and the Quitline. Participating practices will be randomly allocated to one of the 3 arms of the study: The Quit in General Practice intervention, referral to Quitline and standard in-practice management by the GP (control group) Practices would be eligible if they employed a practice nurse. Patients would be eligible if they were current smokers and 18 years of age or more. The aim is to recruit 90 practices in NSW and Victoria and 2250 patients. Data will be collected at 3 points in time, at baseline, 3 and 12 month post baseline. At baseline data will be collected on demography, smoking history, previous quit attempts and co-morbidity At 3 and 12 month follow up, data will be collected on smoking status, quit attempts, quit sustainability, use of pharmacotherapy, and the intervention received.

This study will be a multi-site randomised control (RCT) of treatment to enhance healthy living among people with psychotic disorders, specifically targeting smoking, diet and physical activity. These issues are highly prevalent, associated with premature death and reduced quality of life amongst this group. It is expected that the present study will result in the development if an effective treatment program for people with psychotic disorders who have a range of CVD risk factors. We further hypothesise that the Healthy Lifestyles intervention offered to participants in the study will produce greater, more sustainable improvements on CVD risk and smoking status relative to the controls at follow up. The results will better inform the treatment choices of clinicians and will potentially improve the match between treatment and client, improving the health and wellbeing of the group.

Participants suffering H1N1 and requiring admission to an ICU and mechanical ventilation will be followed up after ICU discharge to prospectively record health-related quality of life 6 and 12 months following ICU discharge.

The purpose of this study is to investigate the efficacy of a decision aid (DA) for women with asymptomatic ovarian cancer and rising CA-125 levels after successful first-line treatment. Participants will be randomised to receive either the DA or a control booklet called "Understanding Ovarian Cancer”. All participants will complete an initial questionnaire when they first make their treatment decision, and a follow-up questionnaire 4 months later. It is anticipated that the DA will improve understanding of the treatment options, reduce decisional conflict, increase satisfaction with decision-making, and not increase anxiety, compared to the control booklet.